MARLBOROUGH, Mass., May 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Heart Rhythm Scientific Sessions, in San Francisco on May 8-11.
Safety and efficacy data from the UNTOUCHED study of the Subcutaneous Implantable Defibrillator System (S-ICD) as well as a pooled analysis of data from the Multicenter Automatic Defibrillator Implantation (MADIT) trials will be presented during late-breaking clinical trial sessions on Friday, May 10. Additional data presentations of interest will highlight:
"This year, we're eager to present new data further supporting the use of the S-ICD System as a first-line therapy for patients at risk for sudden cardiac death as well as data underscoring the clinical potential of our future technologies including the POLARx cryoballon ablation catheter and the Lux Dx insertable cardiac monitor," said Dr. Kenneth Stein, senior vice president and chief medical officer, Rhythm Management and Global Health Policy, Boston Scientific. "We are also excited about the presentation of results from MADIT-CHIC, our grant-funded research on the use of cardiac resynchronization therapy in patients with chemotherapy-induced cardiomyopathy, as it is one of the first prospective trials to focus on this growing population."
ABSTRACTS OF INTEREST (listed chronologically)
Thursday, May 9
Heart Failure
S-ICD
WATCHMAN LAAC Device
Transvenous Implantable Cardioverter-Defibrillator (TV-ICD)
Friday, May 10
Heart Failure
Insertable Cardiac Monitor
Electrophysiology
S-ICD
TV-ICD
All presentations are listed in Pacific Daylight Time (PDT) and will take place at Moscone Center. For more information, visit Boston Scientific at Booth #519 or follow @BSCCardiology.
INVESTOR UPDATE
The company will also host an investor event and webcast on May 9 from 9:00-10:00 AM PDT to provide a business update and answer questions from investors about the Boston Scientific Rhythm Management portfolio. The event will be accessible via live webcast at www.bostonscientific.com/investors. A replay of the webcast will be accessible at www.bostonscientific.com/investors beginning approximately one hour following the completion of the event.
The POLARx Cryoablation Catheter and the LUX-Dx Insertable Cardiac Monitor are in development and are not available for use or sale.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
CONTACTS:
U.S. Media:
Laura Aumann
Boston Scientific
(651) 328-0619 (office)
Laura.Aumann@bsci.com
European Media:
Rosie Ireland
Boston Scientific Europe
+44 (0)7585 403359
Rosie.Ireland@bsci.com
Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
(508) 683-5565 (office)
BSXInvestorRelations@bsci.com
SOURCE Boston Scientific Corporation